These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10697444)

  • 1. [Quality assurance of drug therapy for patients with asthma. Health economic analysis].
    Søndergaard B; Thorleifsson S; Herborg H; Frøkjaer B; Hepler CD; Ersbøll BK
    Ugeskr Laeger; 2000 Jan; 162(4):480-6. PubMed ID: 10697444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Community pharmacy-based pharmaceutical care for asthma patients.
    Mangiapane S; Schulz M; Mühlig S; Ihle P; Schubert I; Waldmann HC
    Ann Pharmacother; 2005 Nov; 39(11):1817-22. PubMed ID: 16219893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-of-illness of asthma in Denmark in the year 2000].
    Mossing R; Nielsen GD
    Ugeskr Laeger; 2003 Jun; 165(26):2646-9. PubMed ID: 12886546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost of asthma therapy in relation to severity. An empirical study].
    Graf von der Schulenburg JM; Greiner W; Molitor S; Kielhorn A
    Med Klin (Munich); 1996 Oct; 91(10):670-6. PubMed ID: 9019647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of disease management on outcomes and cost of care: a study of low-income asthma patients.
    Rossiter LF; Whitehurst-Cook MY; Small RE; Shasky C; Bovbjerg VE; Penberthy L; Okasha A; Green J; Ibrahim IA; Yang S; Lee K
    Inquiry; 2000; 37(2):188-202. PubMed ID: 10985112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between pharmaceutical costs, disease severity, and health-related quality of life in asthmatics in Swedish primary care.
    Arnlind MH; Nokela M; Rehnberg C; Jonsson EW
    J Asthma; 2006 Oct; 43(8):585-91. PubMed ID: 17050222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of asthma in Italy: results of the SIRIO (Social Impact of Respiratory Integrated Outcomes) study.
    Dal Negro RW; Micheletto C; Tosatto R; Dionisi M; Turco P; Donner CF
    Respir Med; 2007 Dec; 101(12):2511-9. PubMed ID: 17822890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacoeconomics of asthma].
    Jahnz-Rózyk K; Targowski T
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():48-9. PubMed ID: 15524016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development, implementation, and evaluation of a community pharmacy-based asthma care model.
    Saini B; Krass I; Armour C
    Ann Pharmacother; 2004 Nov; 38(11):1954-60. PubMed ID: 15479780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multisite randomized trial of the effects of physician education and organizational change in chronic asthma care: cost-effectiveness analysis of the Pediatric Asthma Care Patient Outcomes Research Team II (PAC-PORT II).
    Sullivan SD; Lee TA; Blough DK; Finkelstein JA; Lozano P; Inui TS; Fuhlbrigge AL; Carey VJ; Wagner E; Weiss KB
    Arch Pediatr Adolesc Med; 2005 May; 159(5):428-34. PubMed ID: 15867115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the clinical and economic outcomes of pharmacy interventions in drug-related problems.
    Westerlund T; Marklund B
    J Clin Pharm Ther; 2009 Jun; 34(3):319-27. PubMed ID: 19646078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of asthma controller therapies: influence of disease severity and other variables.
    Navarro RP; Parasuraman B
    Manag Care Interface; 2005 Jun; 18(6):31-40. PubMed ID: 16018297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving drug therapy for patients with asthma--part 1: Patient outcomes.
    Herborg H; Soendergaard B; Froekjaer B; Fonnesbaek L; Jorgensen T; Hepler CD; Grainger-Rousseau TJ; Ersboell BK
    J Am Pharm Assoc (Wash); 2001; 41(4):539-50. PubMed ID: 11486980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma.
    Brown R; Turk F; Dale P; Bousquet J
    Allergy; 2007 Feb; 62(2):149-53. PubMed ID: 17298423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
    Sullivan SD; Turk F
    Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol.
    Bukstein DA
    Am J Manag Care; 1997 Nov; 3(11):1701-6. PubMed ID: 10178468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-effectiveness analysis of a peak flow-based asthma education and self-management plan in a high-cost population.
    de Asis ML; Greene R
    J Asthma; 2004 Aug; 41(5):559-65. PubMed ID: 15360065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study.
    Weiss K; Buxton M; Andersson FL; Lamm CJ; Liljas B; Sullivan SD
    Pediatr Allergy Immunol; 2006 May; 17 Suppl 17():21-7. PubMed ID: 16573705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
    Friedman HS; Yawn BP
    Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of a community pharmacy-based rural asthma management service.
    Saini B; Filipovska J; Bosnic-Anticevich S; Taylor S; Krass I; Armour C
    Aust J Rural Health; 2008 Apr; 16(2):100-8. PubMed ID: 18318852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.